Literature DB >> 35040006

The effect of Myo-Inositol supplement on molecular regulation of folliculogenesis, steroidogenesis, and assisted reproductive technique outcomes in patients with polycystic ovarian syndrome.

Maryam Tabatabaie1, Sadegh Amiri1,2, Masoumeh Golestan Jahromi3, Azadeh Akbari Sene1, Zahra Zandieh1,2, Mehdi Mehdizadeh2, Fatemehsadat Amjadi4,5.   

Abstract

RESEARCH QUESTION: The mechanism of Myo-Inositol, as an adjuvant, on key signaling pathways related to oocyte maturation, fertilization rate, and embryo quality as well as ovarian steroidogenesis in cumulus cells of PCOS patients, is still unclear.
DESIGN: Infertile patients who were candidates for ART cycles were divided into three groups (n = 30 in each group), including group 1: PCOS patients only receiving folic acid, group 2: PCOS patients receiving daily Myo-Inositol combined with folic acid, and a control group (group 3): normal ovulatory women without PCOS receiving only folic acid from 1 month prior to IVF cycle until the day of ovum pick up. During the ART procedure, oocytes maturation, fertilization rate, and embryo quality were assessed. The gene expressions of FSHR, LHR, CYP11A1, CYP19A1, 3β-HSD2, and StAR were also analyzed using qRT-PCR. Western blot analysis was performed for the evaluation of AKT, ERK, CREB, and AMPK phosphorylation. RESULT: Despite equal number of retrieved oocytes, the percentages of MII oocytes, fertilization rate, and embryo quality were found to be significantly higher in group 2 due to the administration of inofolic. The expressions of all the studied genes were significantly higher in the cumulus cells of group 1 compared to the group 2. Higher phosphorylation of ERK1/2 was found in the groups 2 and 3 compared to the group 1. On the other hand, p-Akt has significantly decreased in the group 2 compared to the group 1.
CONCLUSION: Our study provides new insight into the molecular mechanism underlying the positive effect of Myo-Inositol on intrinsic ovarian defects in PCOS, steroidogenesis, oocyte maturation, fertilization rate, and embryo quality.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  ART; Molecular mechanism; Myo-Inositol; PCOS

Mesh:

Substances:

Year:  2022        PMID: 35040006     DOI: 10.1007/s11033-021-06833-9

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  6 in total

1.  Can high levels of D-chiro-inositol in follicular fluid exert detrimental effects on blastocyst quality?

Authors:  K Ravanos; G Monastra; T Pavlidou; M Goudakou; N Prapas
Journal:  Eur Rev Med Pharmacol Sci       Date:  2017-12       Impact factor: 3.507

Review 2.  Clinical relevance in present day hormonal contraception.

Authors:  Pedro-Antonio Regidor
Journal:  Horm Mol Biol Clin Investig       Date:  2018-10-26

3.  The luteinizing hormone beta-subunit exon 3 (Gly102Ser) gene mutation and ovarian responses to controlled ovarian hyperstimulation.

Authors:  Robab Davar; Nasim Tabibnejad; Seyed Mehdi Kalantar; Mohammad Hasan Sheikhha
Journal:  Iran J Reprod Med       Date:  2014-10

Review 4.  Myo-Inositol's Role in Assisted Reproductive Technology: Evidence for Improving the Quality of Oocytes and Embryos in Patients With Polycystic Ovary Syndrome.

Authors:  Deepti Gupta; Safeera Khan; Muhammad Islam; Bilal Haider Malik; Ian H Rutkofsky
Journal:  Cureus       Date:  2020-05-12

5.  Association between The Number of Retrieved Mature Oocytes and Insulin Resistance or Sensitivity in Infertile Women with Polycystic Ovary Syndrome.

Authors:  Fatemeh Hassani; Shahrbanoo Oryan; Poopak Eftekhari-Yazdi; Masood Bazrgar; Ashraf Moini; Nahid Nasiri; Azadeh Ghaheri
Journal:  Int J Fertil Steril       Date:  2018-10-02

6.  Melanogenic Effects of Maclurin Are Mediated through the Activation of cAMP/PKA/CREB and p38 MAPK/CREB Signaling Pathways.

Authors:  Young Sun Hwang; Sae Woong Oh; See-Hyoung Park; Jienny Lee; Ju Ah Yoo; Kitae Kwon; Se Jung Park; Jangsoon Kim; Eunbi Yu; Jae Youl Cho; Jongsung Lee
Journal:  Oxid Med Cell Longev       Date:  2019-12-22       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.